Sai Life Sciences has received the Securities and Exchange Board of India’s (SEBI's) approval to raise Rs 5,000 crore through an initial public offering (IPO). The company’s proposed IPO comprises a fresh issue of equity shares worth Rs 800 crore and an OFS of 6.15 crore shares by a promoter, investor shareholders and other shareholders.
Of the IPO proceeds, funds to the tune of Rs 600 crore will be used for debt payment and a portion will be used for corporate general purposes. Kotak Mahindra Capital Company, IIFL Securities, Jefferies India and Morgan Stanley India Company are the Book Running Lead Managers to the issue.
Sai Life Sciences provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to global pharmaceutical innovator companies and biotechnology firms.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: